Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
difluprednate + moxifloxacin
- Development stage
- Phase 3
- Lead developer
- Grevis Pharma
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Moxigrev-DF is a fixed-dose combination ophthalmic emulsion containing the corticosteroid difluprednate and the fluoroquinolone antibiotic moxifloxacin. Developed by Grevis Pharma, it is indicated for the treatment of bacterial eye infections accompanied by inflammation, as well as for managing post-operative inflammation and pain following ocular surgery. Moxifloxacin acts as a broad-spectrum antibacterial agent by inhibiting bacterial DNA gyrase and topoisomerase IV, which are essential for bacterial DNA replication and repair. Difluprednate is a potent synthetic glucocorticoid that binds to glucocorticoid receptors to suppress the synthesis of inflammatory mediators like prostaglandins, thereby reducing ocular redness, swelling, and pain.
- Brand names
- 4 Quin DFDiflumoxMilflox DFMolfox DFMoxigrev-DFMoxiyst-DFMozin DFViflunate M
- Other names
- difluprednate + moxifloxacin ophthalmic emulsiondifluprednate and moxifloxacinmoxifloxacin + difluprednatemoxifloxacin and difluprednatemoxifloxacin and difluprednate ophthalmic emulsion
02
Targets
DNA gyraseTopo IV (Bacterial Topoisomerase IV)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on difluprednate + moxifloxacin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on difluprednate + moxifloxacin.